Therapeutics– tag –

Introduction: The Gap Between Aging Biology and Everyday Oncology In earlier parts of this Expert Series, we have explored: Epigenetic clocks and ImAge as tools to quantify “how old” tissues and cells are Tissue- and genotype-specific pr...

Introduction: Adding Lifestyle and Environment to the Genetics–Aging Framework In previous parts of this Expert Series, we focused primarily on “internal” factors: Epigenetic clocks and ImAge as tools to visualize aging Tissue- and genot...

Introduction: Questioning the Dogma that “Aging = More Cancer” In previous parts of this Expert Series, we have discussed: Tools such as epigenetic clocks and ImAge to “visualize” aging Tissue-specific aging profiles and genetic backgrou...

Introduction: Why It Is Hard to Model Aging and Cancer Together In earlier parts of this Expert Series, we have discussed: Tools to visualize aging (epigenetic clocks, single-cell profiling, image-based metrics) Tissue-specific aging pro...

Introduction: Reproductive Aging as a Hub Between Women’s Aging and Cancer In Parts 1–3 of the Expert Series, we discussed: Tools to “visualize” aging (epigenetic clocks, single-cell profiles, image-based metrics) Tissue-specific aging p...

Introduction: Beyond “Aging → Cancer” to “Cancer → Aging” In the Introductory and earlier Expert Series articles, we mainly focused on the direction: Aging increases the risk of cancer Tissue- and genotype-specific aging patterns shape w...

Introduction: Aging Is Not Uniform Across the Body In Part 1 of the Expert Series, we focused on “making aging visible” through epigenetic clocks, single-cell analyses, and image-based metrics. We saw that people of the same chronologica...

Introduction: From the Introductory Series to the Expert Series In the Introductory Series (Parts 1–7), we approached the relationship between aging and cancer from multiple angles—historical, molecular, immunologic, organ-level, lifesty...

FDA approval summary On December 17, 2025, the U.S. Food and Drug Administration (FDA) granted regular approval to rucaparib (Rubraca, pharmaand GmbH) for adult patients with metastatic castration-resistant prostate cancer (mCRPC) associ...

Introduction: Screening Is Not Just “The Earlier, the Better” In Parts 1–5, we explored the relationship between aging and cancer from multiple angles: molecular and genetic mechanisms, immune aging, organ-specific aging profiles, and li...

FDA approval summary On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) in combination with pertuzumab for the first-line treatment of adults with un...

Introduction: Deconstructing Risk Factors In Parts 1–4 of this series, we explored aging and cancer from several angles: Time and historical concepts Molecular and genetic mechanisms Immune aging and the tumor microenvironment Organ- and...

Introduction: Why Do Different Organs Develop Different Cancers with Age? In Parts 1–3, we looked at aging and cancer from the perspectives of time, molecular mechanisms, immunity, and the tumor microenvironment. We saw how aging reshape...

FDA approval summary On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.) with prednisone for adult patients with deleterious or suspected deleteriou...

Introduction: The Triangle of Aging, Cancer, and Immunity In Part 1, we explored why cancer is often described as a “disease of aging” and reviewed the historical and conceptual overlap between the hallmarks of aging and the hallmarks of...

Introduction: Zooming in on the “Inner Structure” of Aging In Part 1, we asked why cancer is often called a “disease of aging” and reviewed how the hallmarks of aging and the hallmarks of cancer overlap. We moved beyond the simple idea t...

Introduction: Why Revisit “Aging and Cancer” Now? The phrase “cancer is a disease of aging” is something most clinicians and life science professionals have heard countless times. Yet very few of us have had the chance to carefully organ...

In Part 3 of this series, we focus on two “second-wave” ADC programs that have attracted considerable attention over the past few months: raludotatug deruxtecan (R-DXd), a CDH6-targeted DXd ADC being co-developed by Daiichi Sankyo a...

In Part 2 of this series, we focus on Enhertu (trastuzumab deruxtecan), the DXd-based ADC from AstraZeneca and Daiichi Sankyo that has already transformed the treatment of advanced HER2-positive and HER2-low breast cancer. At ESMO&n...

Around 2025, oncology is entering a new phase in which antibody–drug conjugates (ADCs) sit at the center of a much broader competition for the “next decade” of cancer care. In this series, we review the most important recent clinical dat...